Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (371-380 of 398) with videos related to

Pageof 40
Sort By:
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registryDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
Seminars in Nuclear Medicine|July 17, 2024
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and PeptidesRichard P Baum, Emil Novruzov, Tianzhi Zhao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2016
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine TumorsStephen A Deppen, Eric Liu, Jeffrey D Blume, et al.
Neoplasia (New York, N.Y.)|November 27, 2020
Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivoFranziska Briest, Eva J Koziolek, Jakob Albrecht, et al.
Dalton Transactions (Cambridge, England : 2003)|August 22, 2017
Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with <sup>152</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Martina Benešová, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Harshad R Kulkarni, et al.
Molecular Imaging and Biology|May 23, 2019
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [<sup>18</sup>F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ UptakeKarine Sahakyan, Xin Li, Martin A Lodge, et al.
The Prostate|May 3, 2018
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working groupAndrea K Miyahira, Kenneth J Pienta, Michael J Morris, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2021
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [<sup>177</sup>Lu]Lu-PSMA-617: a WARMTH multicentre studyHojjat Ahmadzadehfar, Ralf Matern, Richard P Baum, et al.
Nuklearmedizin. Nuclear Medicine|February 17, 2015
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]T D Poeppel, C Boy, A Bockisch, et al.
Pageof 40

Showing results (371-380 of 398) with videos related to

Sort By:
Pageof 40
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registryDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.
Seminars in Nuclear Medicine|July 17, 2024
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and PeptidesRichard P Baum, Emil Novruzov, Tianzhi Zhao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 16, 2016
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine TumorsStephen A Deppen, Eric Liu, Jeffrey D Blume, et al.
Neoplasia (New York, N.Y.)|November 27, 2020
Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivoFranziska Briest, Eva J Koziolek, Jakob Albrecht, et al.
Dalton Transactions (Cambridge, England : 2003)|August 22, 2017
Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with <sup>152</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Martina Benešová, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOCRichard P Baum, Aviral Singh, Harshad R Kulkarni, et al.
Molecular Imaging and Biology|May 23, 2019
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [<sup>18</sup>F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ UptakeKarine Sahakyan, Xin Li, Martin A Lodge, et al.
The Prostate|May 3, 2018
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working groupAndrea K Miyahira, Kenneth J Pienta, Michael J Morris, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2021
The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [<sup>177</sup>Lu]Lu-PSMA-617: a WARMTH multicentre studyHojjat Ahmadzadehfar, Ralf Matern, Richard P Baum, et al.
Nuklearmedizin. Nuclear Medicine|February 17, 2015
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]T D Poeppel, C Boy, A Bockisch, et al.
Pageof 40